13.76
4.44%
-0.64
After Hours:
13.67
-0.09
-0.65%
Grail Inc stock is traded at $13.76, with a volume of 712.09K.
It is down -4.44% in the last 24 hours and down -2.48% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
See More
Previous Close:
$14.40
Open:
$14.42
24h Volume:
712.09K
Relative Volume:
0.66
Market Cap:
$430.65M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.52%
1M Performance:
-2.48%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
650-771-9796
Address
1525 O'BRIEN DRIVE, MENLO PARK
Grail Inc Stock (GRAL) Latest News
Biotech company Grail to lay off 350, more than half in Bay Area - MSN
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success - Seeking Alpha
Closing Strong: GRAIL Inc. (GRAL) Ends at 13.04, Down -6.52 from Last Close - The Dwinnex
Gleeds to relocate to new Fitzrovia HQ - FMJ
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture - ANTARA English
Gleeds to move into new London HQ next January - Building
Ex-Linchpin director loses appeal of $150,000 penalty - Lawyerly
486 Shares in Graham Holdings (NYSE:GHC) Purchased by King Luther Capital Management Corp - Defense World
Illumina Wins Court Fight With EU Over $7 Billion Grail Deal - MSN
BreakingviewsLarry Fink’s private index dream may be holy grail - Reuters
John P. Mullen Sells 6,718 Shares of Guidewire Software, Inc. (NYSE:GWRE) Stock - Defense World
(09/18/24) GRAL: An Intriguing Biotech Name Active in Cancer Detection Test - Moneyshow.com
Illumina/Grail: EU Court overturns approach to “killer acquisitions” - JD Supra
With 59% ownership of the shares, GRAIL, Inc. (NASDAQ:GRAL) is heavily dominated by institutional owners - Simply Wall St
We're Keeping An Eye On GRAIL's (NASDAQ:GRAL) Cash Burn Rate - Yahoo Finance
Commission withdraws several decisions in the Illumina/GRAIL case - EU Reporter
Cœuré: Illumina/Grail decision will cause “more fragmented system” - Global Competition Review
Grail’s Potential Turnaround: Seeking FDA Approval For Galleri (NASDAQ:GRAL) - Seeking Alpha
GRAIL to focus on multi-cancer early detection; cuts workforce by 30% - MSN
Battery company says it's achieved breakthrough charging time with 'holy grail' of EV tech: 'This car [ticks] all the boxes' - The Cool Down
Illumina Wins Appeal in Europe Over Grail Acquisition, Avoids €432M Fine - Zenopa
Opinion | Illumina’s Antitrust Vindication - The Wall Street Journal
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void - geneonline
Illumina/GRAIL: ECJ Rules European Commission Lacks Jurisdiction to Review Merger Falling Below EU and National Merger Thresholds - Cleary Gottlieb
Illumina Wins Appeal Against European Commission - MD+DI
Below the thresholds but on the radar | What’s next after the ECJ's Illumina/Grail judgment? - Mayer Brown
EU’s Merger Powers Take Hit in Illumina-Grail Court Defeat - MSN
Cellular Health Screening Test Market Set to Witness Significant Growth by 2024-2031: GRAIL, Inc, OmegaQuant, - EIN News
Illumina avoids hefty EU fine over Grail merger - pharmaphorum
European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine - MSN
Illumina/Grail : EU Court Overturns Below-Threshold Merger Review Policy - Wilson Sonsini
European Court of Justice vacates decision in Illumina-Grail saga - BioWorld Online
Recon: Top EU court favors Illumina over EU regulators in Grail deal; US will still pay more for drugs than its peers after Medicare price negotiations - Regulatory Focus
Greek Regulator Investigates Novartis for Alleged Unfair Practices - PYMNTS.com
Illumina’s European Court Victory Can’t Salvage Grail Acquisition, But It Nullifies Hefty Fine - MedCity News
EU’s ability to challenge ‘killer acquisitions’ dealt a blow by Europe’s highest court - EURACTIV
Illumina wins court battle with EU over $7 billion Grail takeover - Business Standard
Illumina avoids fine for Grail purchase in European court victory - BioPharma Dive
Illumina avoids fine for Grail purchase in European court victory - MedTech Dive
EU high court hands Illumina consolation prize, ruling in favor of its appeal over Grail - Fierce Biotech
Illumina-Grail Deal Was Wrongly Probed by EU, Top Court Rules - Bloomberg
Illumina Wins Court Fight With EU Over $7 Billion Grail Takeover - MSN
European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine - Benzinga
Illumina Wins EU Top Court’s Support in Grail Acquisition - TipRanks
EU court backs Illumina and dismisses challenge over Grail acquisition - Medical Device Network
Critical News & Insights on European Politics, Economy, Foreign Affairs, Business & Technologyeuropeansting.com - The European Sting
EU’s merger powers take hit in Illumina-Grail court defeat - Luxembourg Times
Illumina wins Grail battle in blow to EU merger power - Yahoo Finance
Illumina wins Grail battle in blow to EU merger power - Reuters
Illumina wins legal battle over Grail deal in EU; avoids €432M fine - MSN
Grail Inc Stock (GRAL) Financials Data
There is no financial data for Grail Inc (GRAL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):